1 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates


Journal of the American Academy of Dermatology
Sous presse. Epreuves corrigées par l'auteur. Disponible en ligne depuis le jeudi 28 novembre 2019
Doi : 10.1016/j.jaad.2019.09.017
accepted : 14 September 2019
Predictors of 30-day readmission in Stevens-Johnson syndrome and toxic epidermal necrolysis: A cross-sectional database study

Anthony K. Guzman, MD a, , Myron Zhang, MD b, Shawn G. Kwatra, MD c, Benjamin H. Kaffenberger, MD d
a Division of Dermatology, Department of Internal Medicine, Albert Einstein College of Medicine, Bronx, New York 
b Department of Dermatology, Weill Cornell Medicine, New York, New York 
c Department of Dermatology, Johns Hopkins School of Medicine, Baltimore, Maryland 
d Division of Dermatology, Department of Internal Medicine, Ohio State University Wexner Medical Center, Columbus, Ohio 

Correspondence to: Anthony K. Guzman, MD, 3411 Wayne Ave, 2nd Floor, Ste D, Bronx, NY 10467.3411 Wayne Ave2nd Floor, Ste DBronxNY10467

The predictors of readmission in Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) have not been characterized.


To determine the variables predictive of 30-day readmission after SJS/TEN hospitalization.


We performed a cross-sectional study of the 2010-2014 Nationwide Readmissions Database. Bivariate and multivariable logistic regression was used to evaluate associations of patient demographics, comorbidities, and hospital characteristics with readmission. Aggregate and per-readmission costs were calculated.


There were 8837 index admissions with SJS/TEN reported; of these, 910 (10.3%) were readmitted, with diagnoses including systemic infection (22.0%), SJS/TEN (20.6%), and cutaneous infection (9.1%). Associated characteristics included age 45 to 64 years (odds ratio [OR], 1.88; 95% confidence interval [CI], 1.43-2.49), Medicaid insurance (OR, 1.83; 95% CI, 1.48-2.27), and nonmetropolitan hospital admission (OR, 1.67; 95% CI, 1.31-2.13). Associated comorbidities included HIV/AIDS (OR, 2.48; 95% CI, 1.63-3.75), collagen vascular disease (OR, 2.38; 95% CI, 1.88-3.00), and metastatic cancer (OR, 2.16; 95% CI, 1.35-3.46). The median per-readmission cost was $10,019 (interquartile range, $4,788-$16,485).


The Nationwide Readmissions Database lacks the ability to track the same patient across calendar years. The diagnostic code lacks specificity for hospitalizations <3 days.


Thirty-day readmissions after SJS/TEN hospitalizations are common. Dedicated efforts to identify at-risk patients may improve peridischarge continuity.

The full text of this article is available in PDF format.

Key words : cost analysis, drug reactions, inpatient dermatology, mortality, readmissions, Stevens-Johnson syndrome, toxic epidermal necrolysis

Abbreviations used : ABCD-10, CI, NRD, OR, SCORTEN, SJS, TEN

 Drs Guzman and Zhang contributed equally to this article.
 Reprints not available from the authors.
 Funding sources: None.
 Conflicts of interest: Dr Guzman discloses the receipt of travel reimbursement from Verrica Pharmaceuticals and consulting fees from Cello Health. Dr Kwatra is an advisory board member for Menlo and Trevi Therapeutics, has received grant funding from Kiniksa Pharmaceuticals, and is supported by the Dermatology Foundation. Dr Kaffenberger is an investigator for Biogen, Eli Lilly, and Celgene and is supported by the Dermatology Foundation. Dr Zhang has no conflicts of interest to report.
 IRB approval status: All research activities were performed using publicly available deidentified information, and Institutional Review Board approval was not required.

© 2019  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline
You can move this window by clicking on the headline